Find your next paid study

University of FloridaNCT06184516

Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vacci…

National Cancer Institute (NCI)NCT03606967

~$10 – $5,625

Observational

ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation

This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using elect…

Nicotine DependenceTobacco-Related Carcinoma

Fred Hutchinson Cancer CenterNCT06909500

Gastric CancerPeritoneal Carcinomatosis

A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases

To assess if PD-L1 expression can be upregulated in peritoneal metastases from gastric cancer after the administration of HIPEC with greater frequency compared…

University of ChicagoNCT04107077

Phase 3

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compare…

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

Revolution Medicines, Inc.NCT07805954

~$10 – $8,750

Foregut AdenocarcinomaEsophageal AdenocarcinomaGastroesophageal Adenocarcinoma+6 more

Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy …

Yale UniversityNCT07282912

Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant p…

Prostate Carcinoma

University of Southern CaliforniaNCT06067295

~$10 – $750

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). The study aims to demons…

Bicara TherapeuticsNCT07807163

~$10 – $8,750

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (INTERCEPTioN for Suspected Lung Cancer)for Suspected Lung Cancer)

This study evaluates the effectiveness of tumor samples in providing information about hereditary or cancer specific genetic variants that may have a role in d…

Lung CarcinomaMetastatic Malignant Neoplasm in the Lung

Head & Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerEsophageal Cancer+5 more

~$10 – $750

Mayo ClinicNCT06482073

Phase 1

A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in se…

Sutro Biopharma, Inc.NCT07807345

~$10 – $8,750

Phase 3

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard …

Carcinoma, Non-Small-Cell LungNeoplasm Metastasis

Eli Lilly and CompanyNCT06119581

~$10 – $7,500

Phase 1

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to oth…

Metastatic Malignant Solid NeoplasmPlatinum-Resistant Ovarian High Grade Serous AdenocarcinomaUnresectable Malignant Solid Neoplasm